Sigma Planning Corp Reata Pharmaceuticals Inc Transaction History

Sigma Planning Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 01, 2023	SELL	$79.22 - $105.37 $201,614 - $268,166	-2,545 Reduced 40.27%	3,775 $384,000
Q1 2023 May 05, 2023	SELL	$30.85 - $93.17 $91,778 - $277,180	-2,975 Reduced 32.01%	6,320 $574,000
Q4 2022 Jan 24, 2023	SELL	$22.15 - $42.11 $2,037 - $3,874	-92 Reduced 0.98%	9,295 $0
Q3 2022 Nov 10, 2022	SELL	$19.41 - $36.49 $18,012 - $33,862	-928 Reduced 9.0%	9,387 $236,000
Q2 2022 Aug 11, 2022	BUY	$20.71 - $36.5 $213,623 - $376,497	10,315 New	10,315 $313,000
Q4 2021 Feb 02, 2022	SELL	$25.61 - $110.96 $167,591 - $726,122	-6,544 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$100.0 - $143.02 $18,400 - $26,315	184 Added 2.89%	6,544 $658,000
Q2 2021 Aug 13, 2021	BUY	$78.27 - $151.29 $157,714 - $304,849	2,015 Added 46.38%	6,360 $900,000
Q1 2021 May 06, 2021	BUY	$94.25 - $132.81 $59,377 - $83,670	630 Added 16.96%	4,345 $433,000
Q4 2020 Feb 09, 2021	BUY	$102.03 - $184.62 $379,041 - $685,863	3,715 New	3,715 $459,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

Stay updated on Sigma Planning Corp with notifications on news.